Making Progress Toward Cures
Our Goals
- We provide education, resources, and support to kidney cancer patients and caregivers
- We identify patients’ and researchers’ unmet needs
- We engage and educate policymakers on the urgency of kidney cancer research funding
- We urge Congress to fund kidney cancer research
- We increase CDMRP Kidney Cancer Research Program and NIH funding through advocacy
- We provide direct funding to promising ideas
- We propel collaboration and progress in kidney cancer research (Kidney Cancer Research Summit)
- We grow the community of kidney cancer researchers
- We support the development of new treatments by educating patients on trial access and enrollment
- We identify new unmet needs, set new goals, and keep working
Our Mission
Our mission is to accelerate cures for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
NEWLY DIAGNOSED?
You’re not alone. We’ve put together a Patient Resource Center to help you navigate a new diagnosis and beyond. Learn about kidney cancer, various treatment options, patient education events, and how to live well with cancer.
BUILD A CARE TEAM
Join Our Grassroots Army
What are we advocating for?
Awareness? Funding? Research? Cures?
@kidneycan Thank you for being there and doing this important advocacy work. Looking good! 🧡
Today, KidneyCAN advocates are on #CapitolHill requesting a $60M appropriation for the #KidneyCancer Research Program (KCRP) in FY24. This funding is crucial for advancing research and ...#acceleratingcures.
We're also asking Congress to allocate $50.9 billion to the #NIH, including $9.988 billion for the #NCI, to bolster #RCC research and development. Every dollar counts in the fight against cancer!
Today, KidneyCAN advocates are on #CapitolHill requesting a $60M appropriation for the #KidneyCancer Research Program (KCRP) in FY24. This funding is crucial for advancing research and ...#acceleratingcures.
We're also asking Congress to allocate $50.9 billion to the #NIH, including $9.988 billion for the #NCI, to bolster #RCC research and development. Every dollar counts in the fight against cancer!
Today, KidneyCAN advocates are on #CapitolHill requesting $60M for the #KidneyCancer Research Program (KCRP) in FY24 and $50.9 billion to the #NIH, including $9.988 billion for the #NCI. This funding... is critical for advancing research and #acceleratingcures!
#AdvocacyInAction
🚨 REMINDER: Last chance to 🗳️ in @ASCO Elections!
⏲️ DEADLINE: Monday, Dec. 4th at 3:00PM EST
Proud to support:
🌟The incomparable GU Oncology legend & ...mentor, @DrChoueiri!
🌟Our indefatigable #ASCOAdvocacy leader & past @ASCO Gov't Relations Committee Chair, @DrJasonWestin!
@montypal @LauraBukavinaMD @CaseUrology @scientistatlrge @FoxChaseCancer @NimaSharifiMD @dsui_miami_uro @lissmike @UTSA @EurUrolOncol @biorxivpreprint @spsutkaMD @DrChoueiri @NazliDizman ...@ZeynepZengin @ERPlimackMD @neerajaiims @shilpaonc @UroOnc We are very excited about our new trial @cityofhope in metastatic #RCC using a powerful combination of Nivo/Ipi with camu camu, a Brazilian berry, which has shown some remarkable efficacy in refractory melanoma
@kidneycan @KidneyCancer @EAUYAU_RenalCa @MOASC_Office @IKCCorg
Great advice from @Robert_Uzzo accepting the Joseph A. Smith Mentorship Award at #SUO23
✅Take Inventory
📉Embrace Failure
⏩Move Forward
🙏Be Grateful
Congratulations! So ...very well deserved.
#FoxChaseProud @FoxChaseCancer @FCUroOnc
It took @KyleBlumMD 6 years of work to develop this sarcomatoid RCC consortium. Willing to bet that breakthroughs regarding this aggressive RCC phenotype are going to culminate from his hard work!
Latest News
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program). Our work is funded by grassroots donors in the kidney cancer community.
